Anti-vascular Endothelial Growth Factor Therapeutics Market by Therapeutic Type (Monoclonal Antibodies, Tyrosine Kinase Inhibitors), Route of Administration (Intravitreal Injections, Oral Administration), Indication - Global Forecast 2024-2030
The Anti-vascular Endothelial Growth Factor Therapeutics Market size was estimated at USD 8.49 billion in 2023 and expected to reach USD 9.01 billion in 2024, at a CAGR 8.85% to reach USD 15.38 billion by 2030.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Anti-vascular Endothelial Growth Factor Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Anti-vascular Endothelial Growth Factor Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Anti-vascular Endothelial Growth Factor Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Alteogen Inc., Amgen Inc., Arechar Healthcare, Aurobindo Pharma, Bausch Health Companies Inc., Bayer AG, Biogen Inc., Cipla Ltd., Coherus BioSciences, Inc., Delphis Pharmaceutical India, F. Hoffmann-La Roche AG, Hetero Healthcare Limited, Intas Pharmaceuticals Ltd., Natco Pharma Limited, Novartis AG, Pfenex Inc., Pfizer Inc., Regeneron Pharmaceuticals Inc., Samsung Bioepis, Sandoz Canada Incorporated, Shilpa Medicare Ltd., Sun Pharmaceutical Industries Inc., Teva Pharmaceutical Industries Ltd., Viatris Inc., and Xbrane Biopharma.
Market Segmentation & Coverage
This research report categorizes the Anti-vascular Endothelial Growth Factor Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:
Therapeutic Type
Monoclonal Antibodies
Intravitreal Injections
Diabetic Macular Edema
Americas
Argentina
California
Australia
Denmark
The report offers valuable insights on the following aspects:
- Market Penetration: It presents comprehensive information on the market provided by key players.
- Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
- Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
- Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
- Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
- What is the market size and forecast of the Anti-vascular Endothelial Growth Factor Therapeutics Market?
- Which products, segments, applications, and areas should one consider investing in over the forecast period in the Anti-vascular Endothelial Growth Factor Therapeutics Market?
- What are the technology trends and regulatory frameworks in the Anti-vascular Endothelial Growth Factor Therapeutics Market?
- What is the market share of the leading vendors in the Anti-vascular Endothelial Growth Factor Therapeutics Market?
- Which modes and strategic moves are suitable for entering the Anti-vascular Endothelial Growth Factor Therapeutics Market?
Note: PDF & Excel + Online Access - 1 Year
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 4.1. Introduction
- 4.2. Anti-vascular Endothelial Growth Factor Therapeutics Market, by Region
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Rise in the prevalence of ophthalmic diseases
- 5.1.1.2. Increasing number of geriatric population with eye disorders
- 5.1.1.3. Growing awareness about anti-VEGF treatment
- 5.1.2. Restraints
- 5.1.2.1. Unfavorable reimbursement scenario for anti-VEGF treatment
- 5.1.3. Opportunities
- 5.1.3.1. Ongoing research activities to develop advanced therapeutics
- 5.1.3.2. Surge in drug approvals from regulatory bodies
- 5.1.4. Challenges
- 5.1.4.1. Concern regarding intraocular injuries in anti-VEGF treatment
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework
- 6. Anti-vascular Endothelial Growth Factor Therapeutics Market, by Therapeutic Type
- 6.1. Introduction
- 6.2. Monoclonal Antibodies
- 6.3. Tyrosine Kinase Inhibitors
- 7. Anti-vascular Endothelial Growth Factor Therapeutics Market, by Route of Administration
- 7.1. Introduction
- 7.2. Intravitreal Injections
- 7.3. Oral Administration
- 8. Anti-vascular Endothelial Growth Factor Therapeutics Market, by Indication
- 8.1. Introduction
- 8.2. Diabetic Macular Edema
- 8.3. Retinal Vein Occlusion
- 8.4. Wet Age-Related Macular Degeneration
- 9. Americas Anti-vascular Endothelial Growth Factor Therapeutics Market
- 9.1. Introduction
- 9.2. Argentina
- 9.3. Brazil
- 9.4. Canada
- 9.5. Mexico
- 9.6. United States
- 10. Asia-Pacific Anti-vascular Endothelial Growth Factor Therapeutics Market
- 10.1. Introduction
- 10.2. Australia
- 10.3. China
- 10.4. India
- 10.5. Indonesia
- 10.6. Japan
- 10.7. Malaysia
- 10.8. Philippines
- 10.9. Singapore
- 10.10. South Korea
- 10.11. Taiwan
- 10.12. Thailand
- 10.13. Vietnam
- 11. Europe, Middle East & Africa Anti-vascular Endothelial Growth Factor Therapeutics Market
- 11.1. Introduction
- 11.2. Denmark
- 11.3. Egypt
- 11.4. Finland
- 11.5. France
- 11.6. Germany
- 11.7. Israel
- 11.8. Italy
- 11.9. Netherlands
- 11.10. Nigeria
- 11.11. Norway
- 11.12. Poland
- 11.13. Qatar
- 11.14. Russia
- 11.15. Saudi Arabia
- 11.16. South Africa
- 11.17. Spain
- 11.18. Sweden
- 11.19. Switzerland
- 11.20. Turkey
- 11.21. United Arab Emirates
- 11.22. United Kingdom
- 12. Competitive Landscape
- 12.1. FPNV Positioning Matrix
- 12.2. Market Share Analysis, By Key Player
- 12.3. Competitive Scenario Analysis, By Key Player
- 13. Competitive Portfolio
- 13.1. Key Company Profiles
- 13.1.1. Alteogen Inc.
- 13.1.2. Amgen Inc.
- 13.1.3. Arechar Healthcare
- 13.1.4. Aurobindo Pharma
- 13.1.5. Bausch Health Companies Inc.
- 13.1.6. Bayer AG
- 13.1.7. Biogen Inc.
- 13.1.8. Cipla Ltd.
- 13.1.9. Coherus BioSciences, Inc.
- 13.1.10. Delphis Pharmaceutical India
- 13.1.11. F. Hoffmann-La Roche AG
- 13.1.12. Hetero Healthcare Limited
- 13.1.13. Intas Pharmaceuticals Ltd.
- 13.1.14. Natco Pharma Limited
- 13.1.15. Novartis AG
- 13.1.16. Pfenex Inc.
- 13.1.17. Pfizer Inc.
- 13.1.18. Regeneron Pharmaceuticals Inc.
- 13.1.19. Samsung Bioepis
- 13.1.20. Sandoz Canada Incorporated
- 13.1.21. Shilpa Medicare Ltd.
- 13.1.22. Sun Pharmaceutical Industries Inc.
- 13.1.23. Teva Pharmaceutical Industries Ltd.
- 13.1.24. Viatris Inc.
- 13.1.25. Xbrane Biopharma
- 13.2. Key Product Portfolio
- 14. Appendix
- 14.1. Discussion Guide
- 14.2. License & Pricing
- FIGURE 1. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET RESEARCH PROCESS
- FIGURE 2. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, 2023 VS 2030
- FIGURE 3. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
- FIGURE 5. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET DYNAMICS
- FIGURE 7. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2023 VS 2030 (%)
- FIGURE 8. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 9. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
- FIGURE 10. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 11. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
- FIGURE 12. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 13. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 14. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 15. UNITED STATES ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 16. UNITED STATES ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 17. ASIA-PACIFIC ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 18. ASIA-PACIFIC ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 21. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
- FIGURE 22. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook